<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" > <channel><title>Comments on: On prescription drug costs</title> <atom:link href="http://www.kevinmd.com/blog/2004/09/on-prescription-drug-costs.html/feed" rel="self" type="application/rss+xml" /><link>http://www.kevinmd.com/blog/2004/09/on-prescription-drug-costs.html</link> <description></description> <lastBuildDate>Tue, 14 Feb 2012 17:18:00 +0000</lastBuildDate> <sy:updatePeriod>hourly</sy:updatePeriod> <sy:updateFrequency>1</sy:updateFrequency> <xhtml:meta xmlns:xhtml="http://www.w3.org/1999/xhtml" name="robots" content="noindex" /> <item><title>By: Anonymous</title><link>http://www.kevinmd.com/blog/2004/09/on-prescription-drug-costs.html#comment-51666</link> <dc:creator>Anonymous</dc:creator> <pubDate>Tue, 21 Sep 2004 22:48:00 +0000</pubDate> <guid isPermaLink="false">http://clients.emmense.com/kevinmd/2004/09/on-prescription-drug-costs.html#comment-51666</guid> <description>how about the NIH funding Phase IV clinical trials for generic medicines in new indications?&lt;br /&gt;&lt;br /&gt;seems like a good use of public resources to do what private industry wouldn&#039;t (no economic motive).  could be very interesting given that many newer drugs have indications that are more &quot;modern&quot; than the generic that they replace.  it might be a more targeted patient group, it might be a study in conjunction with newer treatments that are closer to current clinical practice, it might be a different dosing schedule.&lt;br /&gt;&lt;br /&gt;it could be difficult to give out $50-100 million dollar grants to do this, especially given the failure rate of drugs in phase IV trials (not as bad as phase III failure rates, but not very good)&lt;br /&gt;&lt;br /&gt;just thinking &lt;br /&gt;&lt;br /&gt;-jeet</description> <content:encoded><![CDATA[<p>how about the NIH funding Phase IV clinical trials for generic medicines in new indications?</p><p>seems like a good use of public resources to do what private industry wouldn&#8217;t (no economic motive).  could be very interesting given that many newer drugs have indications that are more &#8220;modern&#8221; than the generic that they replace.  it might be a more targeted patient group, it might be a study in conjunction with newer treatments that are closer to current clinical practice, it might be a different dosing schedule.</p><p>it could be difficult to give out $50-100 million dollar grants to do this, especially given the failure rate of drugs in phase IV trials (not as bad as phase III failure rates, but not very good)</p><p>just thinking</p><p>-jeet</p> ]]></content:encoded> </item> <item><title>By: Anonymous</title><link>http://www.kevinmd.com/blog/2004/09/on-prescription-drug-costs.html#comment-51649</link> <dc:creator>Anonymous</dc:creator> <pubDate>Fri, 03 Sep 2004 20:09:00 +0000</pubDate> <guid isPermaLink="false">http://clients.emmense.com/kevinmd/2004/09/on-prescription-drug-costs.html#comment-51649</guid> <description>I think that&#039;s a good first step, but even 20-30$ is much cheaper than 100$ per month that many meds cost.</description> <content:encoded><![CDATA[<p>I think that&#8217;s a good first step, but even 20-30$ is much cheaper than 100$ per month that many meds cost.</p> ]]></content:encoded> </item> </channel> </rss>
<!-- Performance optimized by W3 Total Cache. Learn more: http://www.w3-edge.com/wordpress-plugins/

Minified using apc
Page Caching using disk: enhanced
Database Caching 2/6 queries in 0.003 seconds using memcached
Object Caching 353/356 objects using apc
Content Delivery Network via cdn.kevinmd.com

Served from: www.kevinmd.com @ 2012-02-14 12:48:53 -->
